CD274 and neoplasm: Infiltration of tumors with T cells has been associated with favorable responses to PD-(L)1 blockade (3–6), suggesting that strategies which mitigate T cell exclusion from the tumor microenvironment (TME) might improve the efficacy of anti-PD-(L)1 therapies.